Nuvalent Alkazar-NVL-655 vs Alectinib 1st line treatment for ALK+ Non-Small Cell Lung cancer - Clinical Trial
¿Cuál es el Propósito de este estudio?
We are doing this study to find the most effective, safe dose of an experimental drug called NVL-655 (the study drug). We want to know how well the study drug works compared to alectinib, which is a standard treatment for NSCLC.
ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
¿Quién puede participar en el Estudio?
Adults ages 18+ who:
- Are diagnosed with locally advanced or metastatic NSCLC
- Have a documented ALK rearrangement in tissue or blood
- Have not received prior systemic anticancer treatment for NSCLC
For more information, contact the study team at annemarie.peters@duke.edu.
¿Qué Implica?
If you choose to join this study, you will get a random assignment (by chance) to 1 of 2 study groups, Arm A or Arm B.
- If you are in Arm A, you will get the study drug. The study drug comes as a tablet, and you will take it by mouth once per day.
- If you are in Arm B, you will get alectinib. Alectinib is a capsule. You will take it by mouth twice a day.
During the study visits the following procedures may occur: physical examinations, eye examinations, vital signs recording, blood and urine samples collected, electrocardiograms, imaging (CT or MRI) scans, tumor samples, and questionnaires.
The duration of your participation in the study will depend on how long you receive study drug, the overall duration of the study, and how long you are willing to participate. If the research study is stopped prematurely for any reason, your study doctor will tell you and arrange your continuing care.
Detalles del Estudio
